From the article: The nanoparticles are made from cyclodextrins coated with PEG that contain as cargo the anticancer compound camptothecin. The selectivity is apparently not due to the selective uptake of nanoparticles by cancer cells but rather that the interior of cancer cells are more acidic than normal cells. After cells takes up nanoparticles, the nanoparticle breakdown releasing the camptothecin. Because of the lower pH, the break down occurs faster in cancer compared to normal cells.

The New York Times shared drafts of their article with Apple before it was published. In addition, Apple just recently joined the Fair Labor Association. I wonder if the former prompted or accelerated the later.

Currently it is extremely difficult to conduct clinical trials for Alzheimer's Disease (AD) treatments since it takes a long time to determine efficacy. An effective AD biomarker such as this blood test could provide much quicker feedback to tell whether and experimental drug is working or not. See for example: The Role of Biomarkers in Clinical Trials for Alzheimer Disease

A burned out CEO from a company that is in a death spiral (Pfizer) seems like a very unlikely choice. Let's hope that US is not following the same trajectory as Pfizer.

Opps, the above is reversed from what it should be. Inhibition of the RGS14 gene product would theoretically decrease visual memory while increasing hippocampal-based learning and memory.

Inhibiting the RGS14 gene product could be counter productive and in fact dangerous. While this strategy may enhance visual memory, it also may decrease hippocampal-based learning and memory: RGS14

Selecting universities: personal preference and rankings